Figure 1From: Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL Treatment duration for cycle 1 to 5 for CHOEP-14 and CIVEP-14. Back to article page